Abstract
Phakic refractive implantation is a safe and effective treatment option for myopia. This study compared the clinical outcomes of two posterior chamber phakic intraocular lenses: the Phakic Refractive (PR) lens and the Implantable Collamer Lens (ICL). The PR group exhibited lower vaults than those of the ICL group. The PR group had milder glare/halo in the early postoperative period compared to the ICL group, though long-term differences were not significant.
Introduction
For patients with high myopia who are unsuitable for corneal refractive surgeries like LASIK or SMILE, Phakic Intraocular Lenses (PIOLs) offer a reliable alternative. These lenses are surgically implanted into the eye to correct refractive errors. The EVO ICL (Implantable Collamer Lens) is currently the industry standard. However, the Phakic Refractive (PR) IOL has emerged as a new option, featuring a different material (acrylate) and a larger optical zone. This study aims to compare the visual performance and safety of these two lenses using a rigorous contralateral eye design.
Methods
This randomized, double-blind, contralateral eye study involved 19 participants (38 eyes). Each participant received a PR lens in one eye and an EVO ICL in the other. This design effectively controls for individual healing responses and neuroadaptation. Key technical assessments included:
- Vaulting: Measured using Pentacam imaging to ensure a safe distance between the PIOL and the natural lens.
- Optical Quality: Evaluated using the Optical Quality Analysis System (OQAS II) for objective metrics like MTF cutoff and Strehl ratio.
- Subjective Disturbances: Quantified via disk halo testing and patient questionnaires over a 12-month follow-up period.
Key Results and Insights
Both lenses demonstrated excellent safety and efficacy. The efficacy indices (post-op vision vs. pre-op best-corrected vision) were 1.03 for the PR group and 1.01 for the ICL group at one year, with no eyes losing vision.
Vaulting and Safety
The PR lens consistently showed a lower vault compared to the ICL (342.63 µm vs. 470.00 µm at one year, P = 0.010). While both remained within safe clinical ranges, the PR's lower vault suggests a more conservative sizing algorithm. No complications such as cataracts or glaucoma were observed during the study.
Visual Quality and Disturbances
In the early postoperative period (one month), patients reported significantly milder glare and halos in eyes with the PR lens. This advantage is likely attributed to the PR lens's larger 6.0 mm optical zone. However, by the 12-month mark, subjective differences between the two eyes were no longer significant, suggesting effective neuroadaptation.
Objective metrics favored the EVO ICL slightly. It achieved a higher MTF cutoff (34.99 vs 30.08 cpd) and a better Strehl ratio (0.20 vs 0.17), indicating superior objective retinal image sharpness. The PR lens material (acrylate) appeared slightly more pigmented under slit-lamp examination, which may contribute to higher light scattering.
Conclusion and Limitations
Both the PR and EVO ICL are safe and effective for myopia correction. The PR lens offers reduced subjective glare in the early stages, while the EVO ICL provides slightly better objective optical quality. The study's primary limitation is its small sample size (19 patients). Future research with larger cohorts and comparisons against newer lens models, such as the EVO+ ICL, will further clarify the long-term clinical benefits of these technologies.
Summary updated